Who are CG Oncology, Inc.'s main suppliers?

CG Oncology, Inc. (CGON) key suppliers include: BIOVIRE. View the full supplier network at chainsifter.com/chain/CGON.

Who are CG Oncology, Inc.'s major customers?

CG Oncology, Inc. (CGON) key customers include: KISSEI, SP-HEALTHCARE-SPV-I-LLC, Biodexa Pharmaceuticals Plc, Theriva Biologics, Inc.. View the full customer network at chainsifter.com/chain/CGON.

What sector is CG Oncology, Inc. in?

CG Oncology, Inc. (CGON) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

CGON Supply Chain: CG Oncology, Inc. Suppliers & Customers

1Suppliers

4Customers

2Debt Items

20Related Chains

CG Oncology, Inc. Suppliers

Ticker	Name	Confidence	Evidence
BIOVIRE	BIOVIRE	92%	Prior to becoming a majority-owned subsidiary, Biovire was a vendor to the Company and continues to provide clinical supply of cretostimogene used in the Company’s clinical trials.

CG Oncology, Inc. Customers

Ticker	Name	Confidence	Evidence
KISSEI	KISSEI	90%	The Company evaluated the Kissei Territory specific license and related activities under ASC 606, as these transactions are considered transactions with a customer, and identified two material promis…
SP-HEALTHCARE-SPV-I-LLC	SP-HEALTHCARE-SPV-I-LLC	85%	Healthcare, LLC (SafeGuard), purchased a $26.8 million convertible note, including accrued interest, from SP Healthcare SPV I, LLC (the SPV). The SPV used the proceeds from the Note to invest and acq…
BDRX	Biodexa Pharmaceuticals Plc	72%	Reciprocal relationship from BDRX graph: l lawsuits challenging state authority to regulate prescription drug payment limits. Furthermore, in December 2020, the U.S. Supreme Court held unanimously th…
TOVX	Theriva Biologics, Inc.	72%	Reciprocal relationship from TOVX graph: prescribe legally available drugs for off-label uses, drugs may be marketed only for the approved indications and in accordance with the provisions of the app…

CG Oncology, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
CGON-DEBT	Debt stack $7.6M	90%	Market cache reports total debt of $7.6M.
CGON-DEBT-8613	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2024-12-31.

CG Oncology, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for CG Oncology, Inc..

CG Oncology, Inc. Ownership

Holder	Name	Confidence	Evidence
CGON-OWNER-RTW-INVESTMENTS-LP	RTW INVESTMENTS, LP	90%	13F overlay lists RTW INVESTMENTS, LP as top holder; 239 tracked holders.

CG Oncology, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
COGT	Cogent Biosciences, Inc.	100.00	2
JNJ	Johnson & Johnson	100.00	2
RXRX	Recursion Pharmaceuticals, Inc.	100.00	2
SABS	SAB Biotherapeutics, Inc.	100.00	2
TOVX	Theriva Biologics, Inc.	100.00	1	['customer']
URGN	UroGen Pharma Ltd.	100.00	2
TPST	Tempest Therapeutics, Inc.	100.00	2
CRSP	CRISPR Therapeutics AG	100.00	2
GSK	GSK plc	100.00	2
KISSEI	KISSEI	60.75	1	['receiving']
CADL	Candel Therapeutics, Inc.	50.00	2
MCRB	Seres Therapeutics, Inc.	50.00	2
PSTV	Plus Therapeutics, Inc.	50.00	2
TARA	Protara Therapeutics, Inc.	50.00	2
CLDWW	Calidi Biotherapeutics, Inc.	50.00	2
GNLX	Genelux Corporation	50.00	2
SABSW	SAB Biotherapeutics, Inc.	50.00	2
CNSP	CNS Pharmaceuticals, Inc.	50.00	2
AURA	Aura Biosciences, Inc.	36.29	1	['spend']
BDRX	Biodexa Pharmaceuticals Plc	36.29	1	['customer']

CG Oncology, Inc. Supply Chain